

Docket 98D-0969


Lloyd Knight

Wogers

From: Lloyd Knight, AABP, 208-366-2214, fax 208-366-7967

Number of pages with this cover: 2

Fax No: 301-230-1684

My apologies for not contacting you earlier, but would like to share our thoughts with you and seek your support for them as you deem appropriate.

Thanks,
Lloyd Knight
AABP Committee on Pharmaceutical and Biologic Issues

98D-0969

C6

October 4, 1999

Dr. Sundlof,

The American Association of Bovine Practitioners' Committee on Pharmaceutical and Biologic Issues looks forward to participating in the December and February meetings related to antimicrobial resistance in food producing animals.

We strongly feel that the existing degree of risk of antimicrobial resistance in humans due to antimicrobial use in animals should be determined. Without an assessment of the overall risk to people of antimicrobial use in animals, monitoring of effects of policies to reduce resistance in people with changes in antimicrobial use or availability for animals would be meaningless. A reduction in risk implies there is a value for risk.

Likewise, a value for risk is necessary to determine the cost of interventions intended to reduce risk. For example, if an intervention cost \$10,000 and it reduced the risk from an estimated 5 work days lost per case of sickness due to antimicrobial resistance caused by antimicrobial use in food animals to 4.75 work days per case, policy makers would have to decide if the \$40,000 per work day was a good public investment.

Similarly, thresholds should be determined based on calculations intended to show that above a certain level risk will change. If an antibiotic with an easily attainable MIC for a selected pathogen is found to have a small shift in MIC, the risk may remain constant.

In summary, without a beginning assessment of the risk of antimicrobial resistance in humans due to the use of antimicrobials in animals, the need to establish resistance thresholds, change preapproval studies, or the effect of any other policies to reduce risk would be difficult to measure.

We would encourage the participation in the future meetings of Drs. Kathy Ewert and Dave Dargatz. We feel that both have demonstrated knowledge and impartial judgment important to the success of the meetings.

The AABP very much looks forward to participation by member veterinarians and other experts at the Dec. 9-10 and Feb. 22-23 meetings.

Sincerely yours,

Lloyd L. Knight
Committee on Pharmaceutical and Biologic Issues

C O V E R

20 89 RW-2 P100

FAX

S H E E T

To: Jenny Butler
 Fax #: 301-827-6870
 Subject: Faxed submissions to Docket
 Date: 11/2/99
 Pages: 8, including this cover sheet.

COMMENTS:

Pls. log into Docket 980-0969


Thank you!

(I will give a copy to Carol Haley)
Feb

This document is intended only for the use of the party to whom it is addressed. It may contain information that is privileged, confidential, or otherwise protected from disclosure under Federal law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any disclosure, copying, distribution, or action based on the contents of this document is strictly prohibited. If you have received this document in error, please notify me immediately by telephone at the below number, or mail it to the below address.

Thank you.

From the desk of .



Center for Veterinary Medicine
 Policy and Regulations Staff
 7500 Standish Place, HFV-6
 Rockville, Maryland 20855

Phone: 301-
 Fax: 301-827-5510